NCT06717880View on ClinicalTrials.gov

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
Advanced Malignancies
Interventions
DRUG

IBI363 combined with Bevacizumab

"IBI363 will be administrated on Day 1 of every 2 weeks or every 3 weeks, intravenous injection.~Bevacizumab, intravenous injection."

DRUG

IBI363 + Furuitinib

IBI363 Q2W or Q3W IV，Furuitinib po

Trial Locations (1)

430000

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University Hospital, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER